Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.

Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
复制标题

XRCC1基因多态性与肺癌患者临床结局相关性的荟萃分析

DOI:
10.1186/1471-2407-12-71
复制
发表时间:
2012-02-17
期刊:
影响因子:
3.8
通讯作者:
Zhou B
Zhou B
中科院分区:
医学2区
文献类型:
--
作者:
Cui Z;Yin Z;Li X;Wu W;Guan P;Zhou B

文献摘要

参考文献

被引文献

相似文献

x射线修复交叉互补组1 (XRCC1)蛋白在DNA损伤和加合物的修复中起重要作用。xrcc1的单核苷酸多态性(snp)被怀疑与肺癌化疗反应和总生存期有一定关系。本荟萃分析旨在总结已发表的xrcc1最常见snp (Arg194Trp、C b> T、rs1799782和Arg399Gln、G > A、rs25487)与肺癌患者临床结局之间的关联数据。方法从PubMed、EMBASE和中国知网数据库中检索相关文献。采用特定的纳入和排除标准选择研究。主要结局包括客观缓解(即完全缓解+部分缓解vs进展性疾病+稳定性疾病)和总生存期(OS)。估计95%置信区间(CI)的优势比(OR)或风险比(HR)。所有分析均使用Stata软件进行。结果共纳入22篇文献。XRCC1Arg194Trp和Arg399Gln多态性与肺癌患者的治疗反应显著相关。与C/C基因型患者相比,C/T基因型、T/T基因型和Arg194Trp等位基因的小变异T患者更有可能对铂类化疗产生反应(C/T vs C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs C/C: OR, 2.42; 95%CI, 1.88-3.10)。对于xrcc1arg399gln, G/A基因型、A/A基因型和小变异A等位基因与所有患者的客观反应相关(G/A vs G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs G/G: OR, 0.63; 95%CI, 0.49-0.83)。xrcc1arg399gln的G/A和A/A基因型均可影响肺癌患者的总生存率(G/A vs. G/G: HR, 1.23; 95%CI, 1.06 ~ 1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20 ~ 3.45)。交互作用分析表明,与携带C/T+T/T基因型atXRCC1194和G/G基因型atXRCC1399的患者相比,携带194 C/C和399 G/A+A/A或携带194 C/C和399 G/G基因型的患者表现出更差的客观反应。结论xrcc1基因的遗传多态性可能与肺癌患者的总生存期和对铂类化疗的反应有关。
BackgroundX-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) ofXRCC1are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs ofXRCC1(Arg194Trp, C > T, rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients.MethodsWe retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software.ResultsTwenty-two articles were included in the present analysis.XRCC1Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). ForXRCC1Arg399Gln, G/A genotype, A/A genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and A/A genotypes ofXRCC1Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23; 95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the patients carrying C/T+T/T genotype atXRCC1194 and G/G genotype atXRCC1399, the patients carrying 194 C/C and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response.ConclusionsGenetic polymorphisms inXRCC1gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients.
DOI: 10.1128/mcb.14.1.68
发表时间: 1994-01-01
影响因子: 5.3
作者:
CALDECOTT, KW;MCKEOWN, CK;THOMPSON, LH
通讯作者: THOMPSON, LH
DOI: 10.1016/j.lungcan.2008.03.002
发表时间: 2008-11-01
期刊: LUNG CANCER
影响因子: 5.3
作者:
Li, Mingchuan;Yin, Zhihua;Zhou, Baosen
通讯作者: Zhou, Baosen
DOI: 10.3322/canjclin.55.2.74
发表时间: 2005-03-01
影响因子: 254.7
作者:
Parkin, DM;Bray, F;Pisani, P
通讯作者: Pisani, P
DOI: 10.1093/carcin/22.9.1437
发表时间: 2001-09-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Matullo, G;Palli, D;Vineis, P
通讯作者: Vineis, P
DOI: 10.1016/j.mrgentox.2007.03.010
发表时间: 2007-07-28
影响因子: 1.9
作者:
De Ruyck, Kim;Szaumkessel, Marcin;Thierens, Hubert
通讯作者: Thierens, Hubert